Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0002050709-25-000005
Filing Date
2025-08-14
Accepted
2025-08-14 17:22:41
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 9757
2 Squadron_ex1.pdf EX-1 48462
  Complete submission text file 0002050709-25-000005.txt   78391
Mailing Address 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134
Business Address 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134 646 876 3459
RELMADA THERAPEUTICS, INC. (Subject) CIK: 0001553643 (see all company filings)

EIN.: 455401931 | State of Incorp.: NV | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-88207 | Film No.: 251221123
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address P.O. BOX 462 HINSDALE IL 60522
Business Address P.O. BOX 462 HINSDALE IL 60522 8474819500
Squadron Capital Management LLC (Filed by) CIK: 0002050709 (see all company filings)

EIN.: 884254921 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A